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For a long time the brain has been considered an immune-privileged site due to a muted
inflammatory response and the presence of protective brain barriers. It is now recognized
that neuroinflammation may play an important role in almost all neurological disorders
and that the brain barriers may be contributing through either normal immune signaling
or disruption of their basic physiological mechanisms. The distinction between normal
function and dysfunction at the barriers is difficult to dissect, partly due to a lack of
understanding of normal barrier function and partly because of physiological changes that
occur as part of normal development and ageing. Brain barriers consist of a number
of interacting structural and physiological elements including tight junctions between
adjacent barrier cells and an array of influx and efflux transporters. Despite these protective
mechanisms, the capacity for immune-surveillance of the brain is maintained, and there
is evidence of inflammatory signaling at the brain barriers that may be an important part
of the body’s response to damage or infection. This signaling system appears to change
both with normal ageing, and during disease. Changes may affect diapedesis of immune
cells and active molecular transfer, or cause rearrangement of the tight junctions and
an increase in passive permeability across barrier interfaces. Here we review the many
elements that contribute to brain barrier functions and how they respond to inflammation,
particularly during development and aging. The implications of inflammation–induced
barrier dysfunction for brain development and subsequent neurological function are also
discussed.
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INTRODUCTION
It is a long-held belief that the central nervous system (CNS) is
an immune-privileged site, due in part to the muted inflamma-
tory response and presence of several protective brain barriers at
the CNS-peripheral interface. In contrast to this earlier dogma, it
is now evident that the CNS does contain immune capabilities,
and that neuroinflammation is likely to play an important role
in most, if not all, neurological disorders. In addition, the pro-
tective barriers of the brain contribute to these altered functions
through either normal immune signaling, or disruption of the
basic physiological barrier mechanisms. Recent work has shown
that the peripheral immune response contributes to neuroinflam-
matory conditions (Anthony et al., 2011). This has been partic-
ularly well-established in conditions such as multiple sclerosis
(and the corresponding animal model—experimental autoim-
mune encephalomyelitis, EAE) and similar findings have been
Abbreviations: CSF, cerebrospinal fluid; CNS, central nervous system; EAE, exper-
imental autoimmune encephalitis; E, embryonic; Itga6, integrin a6; JAM, junc-
tional adhesion molecule; IL, interleukin; PGP, P-glycoprotein; PKC, protein kinase
C; SVZ, subventricular zone; TNF, tumor necrosis factor; VCAM, vascular cell
adhesion molecule; VZ, ventricular zone, ZO, zonular occludin.
reported in models of amyotrophic lateral sclerosis, stroke, and
epilepsy among others (Campbell et al., 2007b, 2010; Serres et al.,
2009; Auvin et al., 2010).
In all these conditions, changes in blood-brain barrier struc-
ture and function have been reported. The brain barriers play an
important role in maintaining the homeostatic environment of
the CNS, and damage to the various structural and functional
components of the barrier systems may contribute significantly
to disease etiology or progression. What is currently unclear is
how (a) the brain barriers themselves contribute to inflamma-
tory signaling in neurological disease? and (b) which specific
barrier mechanisms are altered in response to inflammation? Of
particular interest to us is the importance of these pathological
mechanisms in the developing brain.
In a typical adult inflammatory state, cells mediating the
inflammatory response arrive at the site of inflammation or infec-
tion and release a large number of mediators that act to control
the accumulation and activation of other cell types (both locally
and migrating). The key features of CNS inflammation include a
range of responses: glial activation, edema, major histocompati-
bility complex expression, systemic acute phase response (general
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inflammation and acute phase protein synthesis), complement
activation, synthesis of inflammatory mediators (e.g., cytokines,
free radicals, prostaglandins) expression of adhesion molecules
and the invasion of circulating immune cells (Perry et al., 1995).
Due to the protective nature of both the blood-brain and blood-
CSF barriers, there are two questions for consideration. Firstly,
are mediators of the inflammatory response captured within the
CNS space unable to be removed rapidly by the bloodstream? And
secondly, does the functional tightness of the barrier impede the
entry of immune cells, thereby slowing the immune response?
Though the brain can mount its own defense by the activation
of resident cells such as astrocytes and microglia (both cell types
that are able to produce and secrete and number of cytokines),
there is still a major reliance on peripheral immune cells. There
is a continued argument about the balance between protection
and damage in the CNS that results from a neuroinflammatory
response, given its limited regenerative capacity (Aguzzi et al.,
2013).
Differentiating the role of inflammatory mediators in patho-
genesis is particularly difficult early in development, as a num-
ber of immune mediators play an important role in normal
brain development. Neuropoietic cytokines contribute to pro-
liferation of neural precursors, fate determination and differen-
tiation, migration of neurons and glia, as well as cell survival
and activity-dependent alteration of synaptic function (Stolp,
2013). Inflammation during development therefore, may cause
widespread injury to the brain—not only due to the damaging
effects of the inflammatory response itself, but also by interfering
with the normal balance of cytokine signaling and therefore CNS
development.
It is nowwell-documented that the barrier systems in the brain
are well-established during early development and are essential
for the normal functioning of the brain (see Saunders et al., 2012
for review). However, other research suggests that the brain barri-
ers may be more susceptible to inflammation-induced changes in
the developing brain (Anthony et al., 1997; Stolp et al., 2005a) in
turn contributing to the pathology of serious neurodevelopmen-
tal disorders such as autism, cerebral palsy and epilepsy (Stolp
and Dziegielewska, 2009). Alterations in signaling through bar-
rier systems following inflammatory injurymay lead to changes in
many elements of brain development—contributing to these seri-
ous developmental disorders [reviewed by Stolp (2013)] or they
may change the susceptibility of the brain to later onset conditions
such as schizophrenia or neurodegenerative disease [reviewed by
Stolp and Dziegielewska (2009); Bilbo and Schwarz (2012)].
The aim of this review is to introduce the brain barrier mech-
anisms and the response and contribution of these barriers to
inflammation in the CNS. We shall initially discuss these issues
in the context of adult disease, before exploring the developmen-
tal barrier systems and their contribution to neurodevelopmental
disorders.
BARRIER MECHANISMS IN THE ADULT AND
DEVELOPING BRAIN
The brain develops and functions within a well-defined internal
environment, which is determined by regulation of interchange
between the main compartments of the CNS, brain, cerebrospinal
fluid (CSF) and the blood, by a combination of physical and
functional mechanisms. These mechanisms, often referred to
by the generic term of “blood-brain barrier,” are present at
three main interfaces in the brain, both in the adult and in the
embryo, although there are some important age-related differ-
ences between them. These interfaces, illustrated in Figure 1, are:
(i) the blood-brain barrier proper at the level of the cerebral
endothelial cells, (ii) the blood-CSF barrier at the epithelial cells
of the choroid plexuses within the four cerebral ventricles and
(iii) the pia arachnoid. There is also an additional barrier inter-
face (iv), present only in the early brain development, between the
CSF and the brain interstitial fluid. In both the adult and develop-
ing brain the essential morphological feature of the blood-brain
barrier proper (i) lies in the presence of tight junctions between
the cerebral endothelial cells of the vasculature of the brain both
within the parenchyma and over the surface in the pia-arachnoid.
Compared with other blood vessels there is also a lack of pinocy-
totic vesicles in the cerebral endothelial cells, although there is
some evidence that they may be more frequent in endothelial
cells in the developing brain (Dziegielewska et al., 1979). In the
choroid plexuses (ii), tight junctions are found between inti-
mately apposed epithelial cells. The tight junctions prevent the
intercellular (paracellular) passage of small molecules even in the
very early stages of the developing brain (Ek et al., 2003, 2006).
An important functional consequence of this is that the presence
of tight intercellular junctions enables the cerebral endothelial
cells and choroid plexus epithelial cells to have effective one-way
transport mechanisms (Liddelow et al., 2009; Ek et al., 2010),
which are essential for establishing and maintaining the inter-
nal environment of the brain separate from that of the rest of
the organism. The morphology of the barrier interface over the
surface of the brain (iii) is more complex during early develop-
ment. Thus, in addition to the adult barrier of tight junctions
linking the endothelial cells of blood vessels in the pia arachnoid,
there is a wide array of specialized intercellular junctions over
the pial surface of the brain, which has been described in the rat
embryo (Balslev et al., 1997). From embryonic day 14 (E14), the
progressive appearance of distinct junctional structures between
the glial end feet was observed. Analysis of albumin distribution
at the electron microscopic level suggested that these junctions
may contribute to restriction of diffusion between the subarach-
noid space and the brain interstitial space. However, at E12 and
E14, the intercellular basis for this barrier appeared incomplete,
so it was suggested that basement membrane may be an impor-
tant component of this functionally effective barrier interface
(Balslev et al., 1997). At the CSF-brain interface (iv) lining the
cerebral ventricles, early in embryonic development, the cells of
the neuroependyma (neuroepithelium) are linked by strap junc-
tions (Møllgård et al., 1987), which are an effective limitation to
intercellular diffusion at least for large molecules (Fossan et al.,
1985). During brain development these strap junctions disap-
pear, and in the adult the cells lining the ventricles (ependymal
cells) are linked by gap junctions (Møllgård et al., 1987) that
do not provide a significant restraint to diffusion of even large
molecules fromCSF to brain interstitial fluid (Fossan et al., 1985).
Consequently, in the embryonic brain only, there appear to be
barrier mechanisms that restrict entry of proteins from CSF into
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the brain interstitial fluid. These proteins may be contributing
to some aspects of early brain development such as neurogene-
sis and cellular differentiation in the ventricular zone (VZ), either
by uptake of individual proteins or ligands bound to them (see
below).
In terms of functional exchanges at the brain barrier inter-
faces, these have only been studied in any detail at the blood-brain
and blood-CSF barriers, although much less so during early
development than in the adult brain. Some recent studies have
FIGURE 1 | Protective barriers of the brain. The collective term
“blood-brain barrier” is used to describe four main interfaces between the
central nervous system and the periphery. (i) The blood-brain barrier proper
formed by tight junctions between the endothelial cells of the cerebral
vasculature. It is thought that pericytes (peri.) are sufficient to induce some
barrier characteristics in endothelial cells, while astrocytes (astro.) are able
to maintain the integrity of the blood-brain barrier postnatally. (ii) The
blood-CSF barrier formed by tight junctions between epithelial cells of the
choroid plexus epithelial cells (note the plexus vasculature is fenestrated).
Resident epiplexus (epi.) immune cells are present on the CSF-surface of
the plexus epithelium. (iii) The outer CSF-brain barrier and the level of the
pia arachnoid, formed by tight junctions between endothelial cells of the
arachnoid vessels. (iv) The inner CSF-brain barrier, present only in early
development, formed by strap junctions between the neuroependymal
cells lining the ventricular surfaces. In the adult this barrier is no longer
present. Both the blood-brain and CSF-brain barriers extend down the spinal
cord. The CSF-filled ventricular system is depicted in blue, while CNS brain
tissue is in brown. The lateral ventricular choroid plexuses are shown in red.
Abbreviations: astro, astrocyte; bv, blood vessel; cpec, choroid plexus
epithelial cell; csf, cerebrospinal fluid; peri, pericytes.
used molecular screening techniques to elucidate the range of
genes coding for various proteins involved in transport mech-
anisms that are expressed at these interfaces during fetal or
neonatal stages of brain development. Daneman et al. (2010)
used Affymetrix genechip arrays to compare expression pat-
terns in neonatal and adult mouse cerebral endothelial cells,
while Liddelow et al. (2012, 2013) used both Affymetrix arrays
and high-throughput RNA sequencing to compare gene expres-
sion in mice and rats from E15 embryos and adult choroid
plexuses. These studies are complimented by those of Kratzer
et al. (2012) who used Affymetrix arrays to study gene expres-
sion in rat choroid plexus at several ages between E18 and adult,
and by Marques et al. (2009) of adult mouse choroid plexus using
Illumina whole genome beadchips. Collectively, these studies have
revealed expression of an astonishing array of transcripts for pro-
teins known to be associated with tight junctions, transporters
(both influx and efflux) and ion channels, as well as numerous
enzymes in various metabolic and signal transduction pathways.
Many of these genes are expressed at a higher level (in some
cases two orders of magnitude higher) in the developing cerebral
endothelial and choroid plexus epithelial cells than in the adult. A
major problem, however, is determining whether these high levels
of expression also reflect a higher level of transport. By compar-
ing published data from in vivo transport from blood to brain or
CSF, for example for glucose and amino acids in neonatal animals
(such experiments in fetuses have so far proved to be a technically
intractable problem), it is clear that these high levels of expression
are likely to reflect higher levels of transport in the developing
brain (Saunders et al., 2013). However, because of the overlap in
substrates for different transporters it is not yet possible to be sure
that higher expression always equates to greater transport. Some
examples comparing expression of individual transporter genes
with data on in vivo transport of various amino acids are shown
in Table 1.
Early in brain development, the choroid plexuses are much
more substantial structures compared to the limited level of
vascularization of the brain (Saunders et al., 2013). It seems rea-
sonable to propose that the plexuses may be more important than
the sparse blood vessels for the supply of nutrients and other
essential molecules to the early developing brain [as originally
proposed by Klosovskii and Zhukova (1963)]. If this is the case,
it is not clear whether the access for these materials or immune
cells to the CNS is via diffusion across the CSF-brain interfaces
(internal and external) or if there are also transport mechanisms
in the cells of these interfaces. Such a mechanism for plasma pro-
teins has recently been proposed for choroid plexus epithelial cells
(Liddelow et al., 2012).
So very little is known about the cellular and molecular prop-
erties of the CSF-brain interface in the developing brain that
is not even clear if the transport mechanisms at this inter-
face function similarly to other barriers. It is known that at
some early stages of brain development, at a time when strap
junctions are present at the CSF-brain interface (see above),
plasma-derived proteins found in the CSF (which are present in
a much higher concentration than in adult CSF, Dziegielewska
et al., 1988) are taken up by some of the neuroependymal cells
lining the ventricular system (Figure 2). This phenomenon has
Frontiers in Integrative Neuroscience www.frontiersin.org August 2013 | Volume 7 | Article 61 | 3
Stolp et al. BBB in inflammation and development
been described for both endogenous proteins (e.g., alpha 2-HS
glycoprotein in human fetuses—Møllgård et al., 1988) and exoge-
nously administered non-native proteins (e.g., human albumin
injected into the wallaby—Dziegielewska et al., 1988; or rat—
Balslev et al., 1997). Examples of plasma protein staining in
different animal species are shown in Figure 2. It is not known,
however, if this is selective with respect to individual proteins
(as is seen in the choroid plexus, Liddelow et al., 2009), regions
of the ventricular system or stage of brain development. It is
also unclear whether the functional significance of this protein
uptake lies in the ligands known to be bound to many of these
Table 1 | Comparison of expression of influx transporters and
published reports on transport function in the developing brain.
Transporter Fold change Transport function
Slc16a10 66.8 Iodothyronines T3, T4a
Slc6a15 11.4 Neutral amino acidsb
*Slc40a1 9.6 Ironc
Slc7a11 7.1 Cysteine, glutamateb
Slc4a1 5.5 Anion transporterd, (Cl−-HCO3 exchange)e
Slc6a13 4.6 GABA transporterf
Slc1a4 4.4 Glutamate, neutral amino acidsg
Slc38a4 4.2 Acidic and neutral amino acidsb,g
Slc6a6 4.1 Taurineb
Slc4a4 4.1 Na+-HCO−3 cotransporterd
Slc7a1 4.1 Acidic amino acidsb
Slc39a8 3.3 Zinc transporterh
Expression levels for the E15 and adult mouse choroid plexus. Fold change in
expression compares E15 with adult choroid plexus (positive values are enriched
in the embryo). Superscript numbers indicate published studies showing trans-
port into developing brain or CSF. *Gene product ferroportin-1 identified in
choroid plexus. References: a(Porterfield and Hendrich, 1992); b(Lefauconnier
and Trouve, 1983); c (Morgan and Moos, 2002); d (Damkier et al., 2010); e(Amtorp
and Sorensen, 1974); f (Al-Sarraf et al., 1997); g (Al-Sarraf, 2002); h(Chowanadisai
et al., 2005). Data from Liddelow et al. (2012), adapted from Saunders et al.
(2013).
proteins (e.g., growth factors, vitamins) or in some specific prop-
erties of the individual proteins themselves. It is also unknown
if this internal barrier is able to impede any CNS immune
response.
As a result of the complex array of barrier mechanisms (both
physical and biochemical) that surround the brain both in the
adult and during development, there is great control of both the
passive barrier to diffusion, and of the dynamic transport sys-
tem controlling the internal environment of the CNS. As more
evidence is provided for the movement of ions, plasma proteins,
drugs and other molecules both into and out of the CNS, there
is increasing support for the notion that an interaction with the
immune system is additionally one of the many functions of these
barrier systems.
ADULT RESPONSE TO INFLAMMATION
CELLULAR INFILTRATION INTO THE BRAIN
The CNS is continuously monitored by resident microglia and
blood-borne immune cells such as macrophages, dendritic cells
and T cells that are able to detect damaging agents that would dis-
rupt homeostasis and optimal functioning of neurons and glia.
Normal immune mechanisms in the CNS are often thought of in
a manner different from that seen in the periphery—for instance
the immune response in the brain can be substantial (e.g., in
response to meningitis) but by contrast, a loss of immunity is also
reported (e.g., cerebral infections) (for review see Ousman and
Kubes, 2012) and the muted inflammatory response in the brain
following injury (Andersson et al., 1992) was the original rational
behind the concept of the CNS being an immune-privileged site.
The developing, and ageing, brain appears to have an exacerbated
immune response compared to that normally seen in the adult
(Perry et al., 1995; Campbell et al., 2007a). An important exam-
ple of the interaction of peripheral immune cells with the CNS
is the myeloid origin of the innate CNS immune cells—microglia
(Aguzzi et al., 2013). Additionally, resident bone marrow-derived
perivascular cells inhabit the perivascular space, which directly
communicates with the CSF-filled subarachnoid space. These
cells are able to respond rapidly to inflammatory injury and
FIGURE 2 | Neuroependymal cell uptake of plasma proteins from the
CSF. Coronal, paraffin-embedded section of lateral ventricular wall from
sheep fetuses at embryonic day 40 (E40, A), E60 (B), and E15 mouse
(C) stained to detect endogenous plasma protein. The migrating
neurons in the ventricular zone are strongly stained (arrows), blood
vessels also show a positive staining reaction (unfilled arrowhead).
Protein is also seen precipitated in the CSF (filled arrowheads).
Extensive precipitation of CSF plasma protein can be seen in the
embryonic mouse example displayed in panel (C) (arrowheads, also in
A,B). Choroid plexus epithelial cells individually positive for protein can
also be seen in panel (A) (asterisks). Abbreviations: csf, cerebrospinal
fluid; lvcp, lateral ventricular choroid plexus. Scale bars 50μm in each.
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are continuously replaced by peripheral monocytes (Hickey and
Kimura, 1988). It is therefore essential that the brain-barriers are
able to facilitate entry of these cells into the CNS as part of normal
function. This mechanism for facilitating peripheral immune cell
entry to the CNS, however, appears to be up-regulated in cases
of neuroinflammation (e.g., during stroke and multiple sclero-
sis), and is associated with deleterious effects on pathology (Vexler
et al., 2006; De Vries et al., 2012). There is, therefore, a fine line
between a “helpful” inflammatory response to injury in the CNS
and pathological neuroinflammatory state.
There is still controversy in the field whether or not resi-
dent perivascular cells are able to remove themselves from the
CNS to instigate a peripheral immune reaction following failure
of the CNS to mount an adequate immune response (Matyszak
and Perry, 1998). It has been demonstrated that CNS-derived
antigens can leave the CNS via drainage through lymph nodes—
potentially making CNS antigens available to the periphery with-
out the need for the movement of cells across the blood-brain
barrier (Harling-Berg et al., 1989). An acute phase response
can be initiated in the liver to induced cerebral inflammation,
as a direct result of this type of signaling (Anthony et al.,
2011). From recent evidence it seems more likely that perivas-
cular cells contribute to multiple sclerosis disease progression
(or EAE in animal models) by reactivation of encephalitogenic
T-cells (Mcmahon et al., 2005). Multiple sclerosis is characteri-
zed by substantial diapedesis of T-cells across the blood-brain
barrier, contributing to demyelinating plaques associated with
the disease (Engelhardt and Coisne, 2011; Zaguia et al., 2013).
It is currently unclear whether this is a normal immune/blood-
brain barrier response to myelin antigen presentation (even if the
presence of these antigens themselves is abnormal), or whether
during diseases like multiple sclerosis they are exacerbated as a
result of an abnormal and exaggerated response from the cere-
bral vasculature. Activated T-cells leave lymph nodes and are
likely able to gain additional entry to the CNS across the choroid
plexuses into CSF where they are re-stimulated by meningeal
and choroid plexus antigen presenting cells (Kolmer’s epiplexus
macrophage cells) and produce cytokines. The mechanism for
the entry of these cells across the choroid plexus is unclear, evi-
dence supporting it has been recently reviewed by Engelhardt
and Sorokin (2009). Choroid plexus epithelial cells constitutively
express ICAM-1 and VCAM-2, and MADCAM1 (mucosal vas-
cular addressin cell adhesion molecule 1) during inflammation
on their apical surfaces. This localization means therefore, that
they are not available for the basolateral to apical migration of
the immune cells (blood-to-CSF direction; Wolburg et al., 1999).
This is counterintuitive, considering the high number of leuko-
cytes frequently observed in the CSF under neuroinflammatory
conditions. A recent study has suggested CCR6+ T-cells may
use chemokine CC ligand 20 (CCL20) expressed by the choroid
plexus epithelial cells to migrate across the CNS (Reboldi et al.,
2009) rather than more traditional adhesion molecules, though
P-selectin has also been identified at the choroid plexus epithe-
lial barrier (Wolburg et al., 1999). Following entry of activated
T-cells into the CNS, subpial vessels are activated and expres-
sion of adhesion molecules and chemokines increases, facilitating
the process of T cell entry into the CNS. Typically in a disease
such as multiple sclerosis, these cells will remain in the ablu-
minal perivascular space unless further activated by interactions
with perivascular macrophages and microglia, allowing them
to invade the parenchyma (Ransohoff and Engelhardt, 2012).
An additional new finding proposes that the choroid plexus
epithelial tight junctions lack Claudin3 (Liddelow et al., 2013),
which when knocked out in mice blood-brain barrier endothe-
lial cells causes increased peripheral immune cell diapedesis
(Wolburg et al., 2003) suggesting that the choroid plexus has the
junctional make-up to allow infiltration of peripherally derived
immune cells and monitoring, without a destruction of other
barrier mechanisms—important for the maintenance of the CNS
internal milieu.
Immune surveillance, in the absence of specific inflamma-
tory signals is therefore likely to occur primarily through the
blood-CSF barrier, facilitated by the specific composition of the
junctions between epithelial cells. Importantly, junctional rear-
rangement appears to be an essential element of inflammation-
induced cellular recruitment to the brain.
The passage of immune cells through the blood-brain bar-
rier is not a simple process and requires a sequential inter-
action between different type of molecules on the surfaces of
immune cells and endothelial cells. This process has been well
described and extensively reviewed (see Banks and Erickson,
2010; Engelhardt and Coisne, 2011; Greenwood et al., 2011).
Briefly, adhesion molecules including VCAM-1 on endothelial
cells bind to leukocyte integrins, initiating a number of signal-
ing processes that ultimately combine with a number of adhesion
molecules allowing a firm attachment between the cell types,
and reorganization of the endothelial cytoskeleton to allow dia-
pedisis to occur. This may include changing the interactions
between the paracellular tight junctions (Greenwood et al., 2003;
Carman and Springer, 2004) facilitating diapedisis via a para-
cellular route, as well as transcellular route, and potentially
causing increased permeability to the solutes in plasma as well
as the white blood cells. To facilitate this process, inflamma-
tory stimuli can induce redistribution of junctional adhesion
molecule A (JAM-A/F11r) away from the cell-to-cell junctions
between endothelial cells. Inhibition of this redistribution can
reduce the migration of monocytes and neutrophils (Stamatovic
et al., 2012), supporting the concept that rearrangement of tight
junction proteins facilitates infiltration of leukocytes into the
brain via a paracellular route during inflammation. The ear-
lier onset of EAE in Pecam1 knock-out mice also suggests that
weak junctional attachments between cells may sensitize the bar-
rier to injury (Graesser et al., 2002). However, in this instance
only increased white blood cell infiltration has been reported
rather than increased permeability to solutes (discussed below).
Peripheral cytokines stimulate this whole process by causing
endothelial cells to increase expression of cell adhesion molecules
on their surface, including selectins, ICAM-1, and VCAM-1
(Meager, 1999), in turn causing alterations in the effectiveness
of immune cell penetration to the CNS. It has been shown that
during the induction of EAE, endothelial cells forming the blood-
brain barrier display an increase in the level of CCL2 proteins
(also known as monocyte chemoattractant protein 1, MCP-1).
CCL2 is the ligand of the activated mononuclear immune cell
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receptor, CCR2, effectively increasing the number/rate entry of
these peripheral immune cells across the blood-brain barrier
(Sagar et al., 2012).
Upon entry to the CNS, immune cells can either set up res-
idence in the glia limitans and monitor the health of CNS cells
(as is the case with perivascular cells—see above) or they can
immediately move further into the nervous tissue to stage fur-
ther immune responses. If no inflammatory mediator/antigen is
present upon entry to the glia limitans, these cells return to the
periphery (Hickey et al., 1991). An equivalent phenomenon has
been recognized in systemic vascular beds (Proebstl et al., 2012;
Alon and Nourshargh, 2013).
CHANGES IN BARRIER PERMEABILITY
Besides the active role of the brain barriers in immune cell infil-
tration into the brain, it is thought that inflammation causes
pathological changes, which result in increased passive perme-
ability of brain barrier to solutes, contributing to exacerbation
of the neuro-inflammatory response. Even in multiple sclero-
sis, where a focus is normally placed on cellular infiltration, the
disruption of the blood-brain barrier tight junctions precedes
the formation of sclerotic lesions (Minagar and Alexander, 2003;
De Vries et al., 2012). Altered zonular occludin 1 (ZO-1) pres-
ence in cerebral microvessels in multiple sclerosis affected brains
has been observed in both normal-appearing white matter and
inactive lesions, in addition to areas with active lesions (Plumb
et al., 2002; Kirk et al., 2003). Altered ZO-1 presence was asso-
ciated with fibrinogen entry into the brain parenchyma even
in the absence of leukocyte recruitment in active lesions (Kirk
et al., 2003). Altered vessel distribution of tight junction proteins
has also been observed in cases of cerebral amyloid angiopa-
thy (Carrano et al., 2012). No white blood cell infiltration has
been reported associated with vessels lacking tight junction pro-
teins, though clumps of microglia in the nearby tissue support the
inflammatory nature of these changes. Increased fibrinogen in the
brain parenchyma suggests, as described above for multiple scle-
rosis that the loss or altered distribution of tight junction proteins
can be associated with increased permeability to solutes from
the blood, without associated cellular infiltration (Carrano et al.,
2012). The blood-CSF barrier may also be affected by inflamma-
tion in this manner, though this barrier has been less extensively
studied (in terms of both solute permeability studies and assess-
ment of tight junction integrity) compared to the blood-brain
barrier. In in vitro experiments, choroid plexus epithelial cell
monolayers showed altered tight junction protein distribution
for CLAUDIN-2 and OCCLUDIN when the cells were exposed
to retrovirally-activated T-cells (Khuth et al., 2005). This cel-
lular interaction or direct administration of pro-inflammatory
cytokines also caused deficits in both active influx transport and
efflux systems in the choroid plexus epithelial cells. In vivo periph-
eral inflammation caused by administration of lipopolysaccha-
ride reduced expression of Claudin3, 5 and 11 in the adult mouse
choroid plexus epithelium (Marques et al., 2009). These in vivo
results are very useful, though it should be noted that other
authors (e.g., Liddelow et al., 2013) when using next generation
RNA sequencing reported no expression of Claudin3 or 5 in the
choroid plexus epithelial cells.
The mechanism by which inflammation causes this change in
tight junction integrity, particularly in the absence of leukocyte
infiltration, is not completely understood. A study from Rigor
et al. (2012) demonstrated protein kinase C-θ (PKC-θ) medi-
ated barrier dysfunction via IL-1β treatment. The authors report
increased PKC-θ activation in an in vitro model of the blood-
brain barrier, followed by decreased transendothelial electrical
resistance. It was proposed that ZO-1 protein phosphorylation
and consequent tight junction disorganization might explain the
low transendothelial electrical resistance after IL-1β exposure
(Rigor et al., 2012). Although suggestive, these in vitro results
require in vivo substantiation of this mechanism. PKC isozymes
are capable of phosphorylating a variety of proteins that reg-
ulate diverse cellular signaling pathways: some proteins related
with cytoskeleton rearrangement, which can affect tight junctions
organization, may be activated as shown via TNFα modulated
of p115RhoGEF phosphorylation (via PKC-α) and consequently
RhoA activation. This activation promotes F-actin rearrangement
and increased endothelial cell permeability in vitro (Peng et al.,
2011), but has not been demonstrated in vivo.
In addition to increased permeability to solutes through the
paracellular pathway following tight junction disruption, new
evidence suggests that up-regulation of pinocytotic activity may
contribute to increased solutes of permeability via a trancellular
route, with no alteration in tight junction morphology (Armulik
et al., 2010). This phenomenon is a well-recognized transport
mechanism in the other biological systems and appears to be reg-
ulated by inflammation [as described, for example by Chidlow
and Sessa (2010)], and needs to be investigated further at the
brain barriers.
INFLAMMATION INDUCED CHANGES IN TRANSPORTERS AT THE
BLOOD-BRAIN BARRIERS
The endothelial cells of the blood-brain barrier and epithelial
cells of the choroid plexus blood-CSF barrier are studded with
many influx and efflux transporters (for review see Saunders
et al., 2013) Transport across the blood–brain barrier and blood–
CSF barrier is directional, with different classes of transporters
involved in movement into (e.g., most SLC transporters) and out
of (e.g., ABC efflux pumps) the brain. Together, these combined
transporters have different effects, ranging from removing solutes
from the brain, preventing their entry into the brain (effluxmech-
anisms), setting up ion gradients or delivering specific nutrients,
ions and other required molecules to the brain cells (influx mech-
anisms). These transporters function normally to maintain the
internal homeostatic milieu of the CNS, however, many trans-
porters at the barrier are altered during inflammation and can
contribute to the overall inflammatory response (Khuth et al.,
2005; VonWedel-Parlow et al., 2009; Erickson et al., 2012).
Alteration in the expression of barrier transporters is not con-
sistent across diseases or disease models. In multiple sclerosis,
endothelial cells display reduced expression of the efflux trans-
porter P-glycoprotein (PGP; Kooij et al., 2010), while in the SOD1
mouse model of amyotrophic lateral sclerosis, PGP is enriched
on vessels within neurodegenerative regions (Jablonski et al.,
2012). In isolated rat brain capillaries, increases of both PGP
activity and protein levels were observed 6 h after TNFα and
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endothelin-1 exposure (Bauer et al., 2007), while in vivo exper-
iments in adult rats evidence suggests that inflammation after
endothelin-1 intrathecal injection increases PGP and BCRP activ-
ity only, without changing the protein levels (Harati et al., 2012).
In contrast, Parkinson’s disease patients present with alterations
in one of the active transport processes at the blood-brain bar-
rier that associate with disease etiology. Polymorphisms in the
Abcb1 gene have been recognized in Parkinson’s disease patients
(Westerlund et al., 2009), and PET studies have shown decreased
function of PGP in Parkinson’s disease (Kortekaas et al., 2005;
Bartels et al., 2008). It is hypothesized that this may contribute
to pathology by increasing the cerebral burden of iron, as well
as sensitizing the brain to damage following pesticide expo-
sure (Bartels, 2011). Developmentally, there are changes in both
gene expression and protein presence of many of these trans-
porters at both the blood-CSF and blood-brain barriers. Ek and
colleagues (2010) showed in the rat that PGP (Abcb1) expres-
sion in both the forebrain and brainstem increased between E13
embryos and adults. MRP1 (Abcc1) expression peaked at birth
and MRP4 (Abcc4) at 1 week postnatally, while BCRP (Abcg2)
levels remained constant through development. This was in con-
trast to the choroid plexus epithelium, which displayed a large
decrease (20-fold) in Abcg2 (BCRP) expression, and increases in
Abcc1 (MRP1) and Abcc4 (MRP4) levels. The authors were able to
also show these changes using immunohistochemistry of protein
levels, suggesting the transcript was active. More recent stud-
ies show that the absolute levels of these transcripts are much
higher at the choroid plexus when compared with the blood vessel
endothelium (Daneman et al., 2010; Liddelow et al., 2012, 2013).
No study to date has investigated the alterations in transcript
or protein following inflammation in developing brain barri-
ers. Increased efflux activity following inflammation, for example
by up-regulation of ABC transporters may be an important
protective mechanism. However, increased expression does not
necessarily equate to increased function. Thus, these data high-
light the importance of not only looking at gene expression and
protein levels, but also transporter activity to try to unveil the
contribution of efflux pumps to inflammation pathophysiology.
Therefore, it is important to keep inmind the different steps in the
inflammatory response and the different inflammation scenarios
that can modulate how brain barriers may contribute in protec-
tive or harmful ways. Thus, due to the effects of inflammation
on various transporters, brain barriers can contribute to changes
in the CNS environment independently, beyond the changes pro-
duced as an associated effect of the activation of immune cells
within the brain.
INFLAMMATORY SIGNALING IN CEREBRAL ENDOTHELIAL AND
EPITHELIAL CELLS
In ischemic stroke, compromised endothelial cells produce
inflammatory cytokines and chemokines including the inter-
leukins IL-1β, IL-8, and CCL2. These cytokines induce expression
of cell adhesion molecules by endothelial cells, facilitating
the movement of peripheral immune cells into the CNS
(Stanimirovic and Satoh, 2000) and potentially contributing to
the initiation of cellular responses to inflammation by microglia
and astrocytes within the brain parenchyma.
Daneman et al. (2010) investigated the transcriptome of puri-
fied blood-brain barrier endothelial cells in postnatal mice and
reported up-regulation of the LPS/IL-1 mediated inhibition of
retinoic x receptor (RXR) pathway in brain endothelial cells
when compared to lung and liver endothelium. Downstream
genes of RXRα were also enriched in cerebral endothelium,
while inhibitory molecules of the receptor were reported only in
peripheral blood vessels. RXRα nuclear receptor can activate the
transcription of numerous molecules and can be inhibited by a
kinase cascade initiated by LPS, IL-1, or TNFα signals. These data
suggest that the RXR pathway may play an important role in the
maintenance of blood-brain barrier immunogenic properties. As
outlined above, however, this pathway has not been investigated
in CNS inflammation to confirm its role in blood-brain barrier
function and dysfunction.
The choroid plexus blood-CSF barrier may also respond to
inflammation by producing different inflammatory mediators,
activating different pathways. Microarray analysis was able to
identify a high number of genes that were up-regulated after
peripheral injection of LPS in adult mice (Marques et al., 2009).
Chemokines, includingCcl4, Ccl5, Ccl7, andCxcl1 as well as inter-
leukins, Il1β, Il6, and Il15, cell adhesion molecules and many
transporter molecules were enriched. Moreover, genes of the
MAPK, NFκB, interferon signaling, and IL-10 pathways were also
identified.
There is increasing evidence that the brain barriers are able to
mount, at least an initial response to peripheral inflammation—
either in reaction to infiltration of inflammatory mediators to the
CNS, or due to the effects of infiltration of activated peripheral
immune cells, and that this vascular inflammatory response may
in itself contribute significantly to neuroinflammatory disease.
DEVELOPMENTAL INFLAMMATORY MEDIATORS AT
THE BRAIN BARRIERS
Recent reports on the transcriptome of the blood-brain
(Daneman et al., 2010) and blood-CSF (Liddelow et al., 2012,
2013; Kratzer et al., 2013) barriers during early development
highlight the alterations in expression levels of a range of tran-
scripts that are involved in the inflammatory response. Combined
with studies looking at brain barrier cells following inflamma-
tory insults (Marques et al., 2009) it is apparent that the brain
barriers are able to take a more active role in responding to
both peripheral and central immune responses than previously
believed. Perinatal brain injury frequently complicates preterm
birth and can lead to significant long-term morbidity. Cytokines
and inflammatory cells are mediators in the common path-
ways associated with perinatal brain injury induced by a variety
of insults, such as hypoxic-ischemic injury, reperfusion injury,
toxin-mediated injury, and infection—all of which cause a rapid
and sometimes sustained immune response. In addition to move-
ment of peripherally produced inflammatory mediators across
the brain barriers, the infiltration of peripheral immune cells can
also alter throughout development. The differential expression of
Icam1 (intercellular adhesion molecule 1) is higher at the blood-
brain barrier than at the blood-CSF barrier (Daneman et al., 2010;
Liddelow et al., 2012; Saunders et al., 2013). The developmental
changes in expression of Icam1 are also different between the two
Frontiers in Integrative Neuroscience www.frontiersin.org August 2013 | Volume 7 | Article 61 | 7
Stolp et al. BBB in inflammation and development
main brain barriers—with no developmental change in expres-
sion in the cerebral vasculature, but a slight increase in expression
in the adult choroid plexus epithelium. Another transcript with
product likely to be involved in the extravasations of peripheral
cells, integrin α6 (Itga6) was also expressed at a higher level at
the blood-brain barrier and was enriched in the adult when com-
pared to postnatal mice (Daneman et al., 2010). In the choroid
plexus Itga6 transcript, though with lower expression than the
cerebral vasculature, was enriched in the embryonic mouse over
7-fold (Liddelow et al., 2013) highlighting the potential devel-
opmental difference in the role of the choroid plexus and blood
vessels in the contribution to immune surveillance of the brain
and the response to inflammation.
The level of peripherally-derived, blood-borne cytokines
entering the brain is low, however, it is comparable to other water-
soluble molecules that are known to cross the brain barriers to a
degree sufficient to affect brain function (e.g., morphine, Banks
et al., 1995). There are a large number of transport systems for
common inflammatory mediators that are present on both the
blood-brain and blood-CSF barriers. IL-1, a pro-inflammatory
cytokine, is able to exert a range of effects on the brain, includ-
ing mediating key host defenses in response to many chronic
CNS diseases. The functional family of IL-1 contains the agonists
(IL-1α and IL-1β), the receptors (IL-1RT1 and IL-1RT2) and a
naturally occurring antagonist molecule (IL-1RN). At the blood-
brain barrier, endothelial cells contain measurable levels of IL-1β
and IL-1RT2 (the receptor with a higher affinity for IL-1β) while
levels of transcript for IL-1α and the type 1 receptor (IL-1RT1) fall
below levels of detection (Daneman et al., 2010). Levels of tran-
script do not appear to change through development, at least in
the mouse. In contrast choroid plexus epithelial cell expression
of IL-1 members shows the predominant receptor transcript that
is detected is IL-1RT1, with over a 10-fold increase in expression
between the embryo and the adult (Liddelow et al., 2012).
Similar to IL-1, IL-6 signals through a cell-surface type I
cytokine receptor complex. It is made up of the ligand-binding
IL-6RA segment (Il6r) and the signal-transduction IL-6RB com-
ponent (Il6st). It should be noted that IL-6RB is also a common
signal-transducer for other cytokines (e.g., LIF, CNTF, IL-11,
among others). Il6 ligand transcript is low in endothelial cells,
however, Il6r and Il6st are high from very early in development
and do not change into adulthood. A similar lack of developmen-
tal expression changes was seen in the choroid plexus with low Il6
and Il6st expression in both embryonic and adult mice (Liddelow
et al., 2012), however, no expression for Il6r was detected in this
study. A more recent RNA sequencing study by these authors,
however, reports expression of Il6r in choroid plexus epithelium
(Liddelow et al., 2013), highlighting the importance of validation
of microarray genechip experiments to ensure no false positive or
negative results.
The levels of transcript for TNFα by barrier cells (both cerebral
endothelium and plexus epithelium) are extremely low, suggest-
ing the majority of TNFα in the CNS is provided by local pro-
duction from other cells types (e.g., microglia—though it is likely
they only produce measurable levels of TNFα following injury),
or by transport from the periphery. Having said this, following
induction of a peripheral inflammatory response, levels of TNFα
(as well as IL-1β) transcript in choroid plexus epithelial cells and
meningeal endothelium increased (Quan et al., 1999). Knock-out
animal models for TNFα receptors Tnfrsf1a (TNFR1/p55 recep-
tor) and Tnfrsf1b (TNFR2/p75 receptor) have shown a reduction
of the ligand penetrating the blood-brain barrier into the spinal
cord, but not into the brain of single knock-out animals (Pan
and Kastin, 2002). Double knock-out animals of both Tnfrsf1a
and Tnfrsf1b showed a complete abolition of TNFα penetration—
suggesting that both receptors are necessary for transporting the
ligand into the CNS (Pan and Kastin, 2002). Genechip data from
the blood-brain barrier (Daneman et al., 2010) show a high
expression of both Tnfrsf1a and Tnfrsf1b, as well as several other
TNFα receptor family members (Tnfrs11a, 12a, 19, and 21) with
no change in expression between early postnatal and adult mice.
At the blood-CSF barrier, plexus epithelial expression of TNFα
receptor family transcripts is low, however, there is embryonic
enrichment of Tnfsf1b and Tnfrsf21.
It therefore appears that while the barrier systems may not
produce a vast array of cytokines under resting conditions, both
in development and adulthood, they express many receptors
for inflammatory mediators and signal amplifiers, indicating the
importance of an early vascular response to inflammatory sig-
naling. Barrier cells also appear able to rapidly up-regulate the
expression, and likely release, of some cytokines following an
inflammatory insult in as little as a few short hours. The capacity
of the barrier cells to respond to inflammatory signaling may be
an important confounding factor in the developmental response
of the brain to inflammation. While it is beyond the scope of this
review, it is important to note that the systemic immune response
is also changing over this time, and may contribute to the dif-
ferences observed in the CNS response to inflammation/injury
during development.
DEVELOPMENTAL INFLAMMATORY RESPONSE
It is now clear that the vasculature in the developing brain is
primed to respond to inflammatory stimuli. Despite this, lit-
tle work has been done to investigate the blood-brain barrier
response to inflammation throughout CNS development. This is
presumably partly due to the historical misconception that the
blood-brain barrier is functionally immature in the developing
brain. However, it has been well-established (as described above)
that the structural and functional mechanism that contribute to
the blood-brain barrier are present from very early in embryoge-
nesis. Work from the last 10 years also suggests that the response
of the blood-brain barrier to inflammation is selective and spe-
cific depending on the age at the time of insult and the location of
the inflammatory signals (discussed below).
Work from our laboratories has shown that systemic inflam-
mation causes a specific increase in the permeability of the
blood-brain barrier in vessels in the periventricular white mat-
ter tract in neonatal rats (Stolp et al., 2005a). The reasons for
the increased permeability in these blood vessels is not yet clear,
though numerous explanations have been presented, including
a developmental delay in the maturity of these vessels or a spe-
cific susceptibility to increased vascular flow. Regarding potential
immaturity of cerebral vessels, work from Virgintino et al. (2004)
and Anstrom et al. (2007) have clearly shown variation in the
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complexity of tight junction proteins in the microvasculature of
the human brain with different developmental ages and brain
regions. While the complexity of the tight junctions has been
much discussed in the context of brain development, it is not yet
clear how well this correlates with barrier permeability (Møllgård
et al., 1979). It is suggested that a delayed maturation of the vessel
structure in the germinal matrix and periventricular white mat-
ter may lead to increased susceptibility of these brain regions to
damage during premature birth, hypoxia, or inflammatory insults
(Anstrom et al., 2007). This is an appealing hypothesis, which rec-
ognizes a maturation process that may be sufficient, for example
in the controlled intrauterine environment, for normal function
but which could be easily damaged by changes in blood pressure
or some other environmental challenge. It has been established,
however, that changes in cerebral blood flow are in themselves
insufficient to account for damage in these brain regions fol-
lowing hypoxia-ischemia (Mcclure et al., 2008). Additionally, the
age specific increase in blood-brain barrier permeability reported
by Stolp et al. (2005a) is not easily explained if the complexity
of the tight junction structure is the only contributing factor in
the vascular response to insult. When a marsupial species was
used to repeat experiments studying the age-specific response
to inflammation, so that a longer developmental period could
be assessed in a postnatal systemic inflammation paradigm, it
was determined that the increased permeability of the periven-
tricular white matter vessels was limited to a specific stage of
development, rather than a general response of the developing
brain (Stolp et al., 2005a). There are two potential explanations
for this: the first that the inflammatory response at the earliest
times is not sufficiently developed to stimulate the signaling path-
way responsible for the increased permeability; or secondly, that
there is a specific combination of factors that occur at the equiv-
alent of the first post-natal week in the rat which combine to
produce the susceptibility of the barrier in these specific vessels.
There is certainly a substantial increase in the number of acti-
vated and migrating microglia and astrocytes in the white matter
at this stage of development (Stolp et al., 2009; Verney et al.,
2010, 2012), which may contribute to the central inflammatory
response and increase the sensitivity of the nearby vessels to the
inflammatory signals. The transcriptome of astrocytes activated
following peripheral LPS inflammation in adults show a marked
increase in the expression of many receptors to cytokines such
as TNFα and TGFβ, however, there is not the same increase in
the expression of the ligands themselves (Zamanian et al., 2012).
There is, however, a relatively high expression of the lipocalin
2 receptor, Slc22a17, which is not present on choroid plexus
epithelium (Liddelow et al., 2013), but is on cerebral endothe-
lium (Daneman et al., 2010) in close association with astrocytic
endfeet. Lipocalin 2 is involved in the innate immune response
by sequestrating iron, in turn limiting bacterial growth (Yang
et al., 2002), and has recently been shown to be the highest
enriched transcript in reactive astrocytes (Zamanian et al., 2012),
suggesting an astrocytic role in the innate immune system and
the acute phase response to infection in the CNS, and there-
fore a potential for an atypical cerebral inflammatory response
when astrocytes are apparently activated by migration during
development.
Interestingly, different developmental barrier susceptibility has
been identified in response to directly induced intracerebral
inflammation. Injection of IL-1β into the striatum of postnatal
day 2 (P2), P21, and adult rats produced a substantial difference
in the inflammatory response (Anthony et al., 1997). A small
increase in neutrophil accumulation was observed at P2 and in
adult animals and a small increase in permeability of vessels to
horseradish peroxidase within the injection site, as well as in the
meningeal vessels. However, in P21 animals there was a signif-
icant increase in permeability of all the vessels in the injected
hemisphere associated with a substantial increase in neutrophil
extravasation into the brain. Subsequent experiments showed that
the changes in permeability were neutrophil dependent, as neu-
trophil depletion by x-irradiation of the bone marrow prevented
this response (Anthony et al., 1997). A neutrophil specific alter-
ation in blood-brain barrier permeability has also been described
in a model of stroke (Fernandez-Lopez et al., 2012). However, in
this case the early postnatal brain appeared to be protected against
altered blood-brain barrier permeability and neutrophil infiltra-
tion, compared to the adult. While various small changes in
vascular structure (e.g., high basal levels of basement membrane
proteins) and activation processes (variable adhesion molecule
expression following stroke) were recognized, Fernandez-Lopez
and colleagues (2012) determined that the reduced response in
neonates was not due to a lack of capacity for neutrophil migra-
tion in early development, but insteadmay be due to altered ratios
of chemoattractant molecules between the systemic and central
systems. This highlights important differences between models
of developmental brain injuries and the etiological mechanisms
involved. There is a clear need for further research in this area to
tease apart specific signaling systems. Particularly given the com-
pletely different response to that seen in the neonatal rat following
systemic inflammation, where no neutrophil infiltration has been
reported in relation to an age and location specific change in
barrier permeability (Stolp et al., 2005a).
The observed developmental differences in the CNS response
to inflammation are likely to reflect a combination of many
aspects of brain development as well as maturation of the sys-
temic inflammatory response. Specific studies are still lacking on
the interactions between these two systems in development, as
has been done in adult neuroinflammatory disease (see Anthony
et al., 2011).
CONSEQUENCES FOR DISEASE AND AGEING
The consequence of the inflammatory signaling process and the
potential association of changes in blood-brain barrier perme-
ability may be widespread in the developing brain. The specific
changes within the developing brain appear to vary depending
on the timing of insult and reflect a mixture of the developmen-
tal stage of the CNS, as well as the specialities of the immune
signaling response of the barrier systems at the time of insult.
In the second half of gestation in the rodent, equivalent to
the 1st—2nd trimester in humans (Clancy et al., 2001), there is
no evidence of blood-brain barrier disruption associated with
experimentally induced inflammation. However, there is sub-
stantial evidence for changes to the developing brain, which
reflect changes in immune signaling. There is a reported decrease
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in (VZ) proliferation, but not the subventricular zone (SVZ),
in response to low dose LPS-induced inflammation in mice at
E13.5 of gestation (Stolp et al., 2011). The change in prolifera-
tion in the VZ but not the SVZ implies a variable contribution
of the vasculature and the CSF for central immune signal-
ing following induction of the systemic maternal inflammatory
response (discussed further below), and indicate that the pro-
genitor cells in the VZ and SVZ are in different environmental
niches (Figure 3). Additional studies confirm the sensitivity of the
VZ cell population to immune signaling, indicating presence of
receptors to specific cytokines (e.g., IL-1β) or pathogen associated
molecules (including TLR2 and 3) and stimulation of these recep-
tors decrease neurogenesis and may alter cellular differentiation
(Lathia et al., 2008; Okun et al., 2010; Crampton et al., 2012).
The change in permeability of the ventricular surface in con-
cert with the decreased proliferation in the VZ (Stolp et al.,
2011) but an absence of altered permeability at the blood-brain
barrier supports the idea of a CSF-brain specific signaling mech-
anism regulating the proliferation of cells in the VZ in early
development. Recent work by Lehtinen et al. (2011) shows that
insulin-like growth factor 1 produced by the choroid plexus in
late gestation in the mousemodulates proliferation of the VZ pro-
genitors. Additionally, a selective fourth ventricle OTX-induced
choroid plexus deletion, which significantly changes the compo-
sition of the CSF, also modifies proliferation in the cortical VZ
throughout gestation (Johansson et al., 2013). Cunningham et al.
(2013) hypothesize that microglia in the developing brain may
be integral to the modulation of proliferation in the progeni-
tor zones of the developing brain, however, their observations
are true for both the VZ and the SVZ and may reflect an addi-
tional level of control, separate to CSF-specific inflammatory
signaling pathways. Substantial changes in the number of F4/80
positive monocytes/microglia within the developing brain were
not observed in a study of low-dose maternal immune regulation
(Stolp HB, unpublished data). The presence of strap junctions
between the neuroependymal cells in early fetal development but
not in the adult (Møllgård et al., 1987), suggest a developmen-
tally important role of junctions between the progenitor cells
in the VZ. It has been suggested that junctions between these
cells are important for regulation of polarity and therefore pro-
liferation in the VZ (Huttner and Brand, 1997). It is possible
that these junctions are modified in response to inflammation
in a similar manner to that described for adult barrier junctions.
Although the presence of strap junctions forming the inner CSF-
brain barrier is only present early in development, there is still
specific uptake of proteins by these neuroependymal VZ cells
(Figure 2)—reiterating the importance of protein-cargo traffick-
ing into the CSF and thence the brain during development (Knott
et al., 1997; Liddelow et al., 2012).
A different response is seen slightly later in the process of
brain development. In early postnatal rodents [approximately
P1–7, equivalent to the 2nd—3rd trimester of human pregnancy,
(Clancy et al., 2001)] increased permeability of the blood-brain
barrier is observed specifically in the periventricular white mat-
ter and associated with damage (Stolp et al., 2005a,b, 2009).
It is currently unclear how much the damage in this area of
the brain is directly related to increased barrier permeability or
other associated phenomenon. Large quantities of plasma pro-
teins in the brain, as occurs with blood-brain barrier breakdown,
have been associated with increased cell death (Nordborg et al.,
1991; Wagner et al., 2002) and altered neuronal function, poten-
tially leading to epileptic-type activity (Friedman, 2011; Tomkins
et al., 2011). It is suggested, however, that changes in blood-
brain barrier permeability associated with systemic inflammation
in postnatal animals is not enough to account for the white
matter damage alone, as it requires increasedmicroglial activation
(Stolp et al., 2009). Increased numbers of microglia, particularly
with the morphological appearance of activation, have been
FIGURE 3 | Neurogenic niches in the developing brain. Dividing cells in
the subventricular zone are closely associated with blood vessels, and the
concept of a neurovascular niche (yellow), which reflects a zone of influence
of vascular factors on neural progenitor cells, suggested in the adult and
developmental subventricular zone. In early development, the dividing cells in
the ventricular zone are not closely associated with the blood vasculature, but
may be affected by trophic factors produced in the CSF, and therefore exist in
a neuroglial-CSF niche. Cells from the ventricular zone migrate toward the
neurovascular niche, before differentiating and migrating to outer cortical
layers of the brain.
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associated with the peak periods of white matter damage (Verney
et al., 2010, 2012; Supramaniam et al., 2013). It is possible that
the large number of migrating, activated microglia within the
white matter tracts are primed to respond to inflammatory sig-
naling transferred through blood vessels, or to the presence of
systemic proteins following blood-brain barrier breakdown, and
it is these immune cells that interact with oligodendrocytes in the
developing white matter to cause injury.
These two scenarios indicate changes to the brain that are an
immediate cause in systemic inflammation and inflammatory sig-
naling into the developing brain. There are likely to bemanymore
examples like this, as numerous immune mediators are impor-
tant for the regulation of maturation processes in the brain (e.g.,
CXCR4 and CXCL7 as key migration cues). It is, however, neces-
sary to also consider subtle changes that may alter the response of
the maturing/ageing brain to insults later in life. One example of
this is a long-term alteration in blood-brain barrier function that
occurs following systemic inflammation early in life. In this case,
the magnitude/prolonged nature of the inflammatory response
is key—and long-term changes in barrier function only occur
after prolonged exposure to systemic inflammatory (Stolp et al.,
2005b).
Given the contribution of the blood-brain barrier to adult
neuroinflammatory diseases (as discussed above), any structural
deficits within the barrier junctions that exist as a result of injury
in early life may increase the risk of early or delayed onset of neu-
rodegenerative conditions [reviewed by Stolp and Dziegielewska
(2009)].
SUMMARY REMARKS
(1) The brain, both in the adult and in development, is sur-
rounded by a complex array of barrier mechanisms com-
prised of morphological (tight junctions), biochemical, and
physiological (influx and efflux transporters) components
that control and determine its internal environment. There
is increasing evidence that one important function is an
interaction with the immune system. Any structural deficits
within the barrier junctions that exist as a result of injury in
early life may increase the risk of early onset of neurodegen-
erative conditions.
(2) Evidence suggests that normal immune surveillance, which
is likely to occur primarily through the blood-CSF barrier,
is facilitated by the specific composition of the junctions
between epithelial cells. Junctional rearrangement appears
to be an essential element of inflammation-induced cellular
recruitment to the brain.
(3) Transporters constitutively present at brain barriers can be
affected by inflammation, therefore contributing to changes
in the CNS environment alone or in association with the
changes produced by the activation of immune cells.
(4) There is increasing evidence that the brain barriers are able
to mount a response to peripheral inflammation and that
this vascular inflammatory response may in itself contribute
significantly to neuroinflammatory disease.
(5) The developmentally controlled CNS response to inflam-
mation is a combination of many aspects of maturation
processes of both the brain and the systemic inflammatory
response itself. Specific study of the interactions between
these two systems in development, as has been done in
adult disease, is very important for proper understanding of
normal and pathological mechanisms involved.
CONCLUSION
The brain barrier systems provide an essential interface between
the periphery and the brain, which is intrinsically involved in
the communication of inflammatory signals between these two
compartments. Though very little is known about the responses
of individual cells forming these barriers during inflammation,
especially during development and ageing, it is apparent that
they respond differentially to disease. We can say with confi-
dence therefore that immunity is an active and fluid component
of normal brain-barrier function. What we cannot say with a sim-
ilar level of confidence, however, is how this function is altered
under stress, or how one should approach these alterations from
a clinical setting. There is still a substantial amount of work
required before specific aspects of changes in the plethora of bar-
rier mechanisms contributing to neuropathological conditions
arising during development and in old age can be defined. More
attention needs to be paid to changes in cellular-based barrier
mechanisms, rather than focus on the integrity of tight junctions,
which has been the emphasis of much of the research effort in this
field so far.
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